Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada
Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada
ABSTRACT IntroductionIn Canada, first and second doses of mRNA vaccines against SARS-CoV-2 were uniquely spaced 16 weeks apart, but the duration of single-dose protection remains uncertain. We estimated one- and two-dose mRNA vaccine effectiveness (VE) among healthcare workers (HCWs) in Quebec, Canada including protection against varying outcome severity, variants of concern (VOC), and the stability of single-dose protection out to 16 weeks post-vaccination. MethodsA test-negative design compared vaccination among SARS-CoV-2 test-positive and weekly-matched (10:1), randomly-sampled, test-negative HCWs using linked surveillance and immunization databases. Vaccine status was defined by one dose ≥14 days or two doses ≥7 days before illness onset or specimen collection. Adjusted VE was estimated by conditional logistic regression. ResultsPrimary analysis included 5,316 cases and 53,160 controls. Single-dose VE was 70% (95%CI: 68-73) against SARS-CoV-2 infection, 73% (95%CI: 71-75) against COVID-19 illness and 97% (95%CI: 92-99) against associated hospitalization. Two-dose VE was 86% (95%CI: 81-90) and 93% (95%CI: 89-95), respectively, with no associated hospitalizations. VE was higher for non-VOC than VOC (73% Alpha) among single-dose (77%, 95%CI: 73-81 versus 63%, 95%CI: 57-67) but not two-dose recipients (87%, 95%CI: 57-96 versus 94%, 95%CI: 89-96). Across 16 weeks, no decline in single-dose VE was observed with appropriate stratification based upon prioritized vaccination determined by higher versus lower likelihood of direct patient contact. ConclusionOne mRNA vaccine dose provided substantial and sustained protection to HCWs extending at least four months post-vaccination. In circumstances of vaccine shortage, delaying the second dose may be a pertinent public health strategy to consider.
Deceuninck Genevi¨¨ve、Brousseau Nicholas、Carignan Alex、De Wals Philippe、Barkati Sapha、Drolet M¨|lanie、Brisson Marc、Boulianne Nicole、Ouakki Manale、Carazo Sara、Sauvageau Chantal、Gilca Rodica、De Serres Gaston、Fortin Elise、Talbot Denis、Skowronski Danuta M.
Centre de Recherche du CHU de Quebec-Universite LavalCentre de Recherche du CHU de Quebec-Universite Laval||Social and preventive medicine department, Faculty of medicine, Laval University||Biological and occupational risks. Institut national de sante publique du QuebecDepartment of Microbiology and Infectious Diseases, Sherbrooke UniversitySocial and preventive medicine department, Faculty of medicine, Laval University||Biological and occupational risks. Institut national de sante publique du QuebecJD MacLean Centre for Tropical Diseases, McGill University Health Centre, McGill University||Department of Medicine, Division of Infectious Diseases, McGill University Health Center, McGill UniversityCentre de Recherche du CHU de Quebec-Universite LavalCentre de Recherche du CHU de Quebec-Universite Laval||Social and preventive medicine department, Faculty of medicine, Laval University||Department of Infectious Disease Epidemiology, Imperial College LondonBiological and occupational risks. Institut national de sante publique du QuebecBiological and occupational risks. Institut national de sante publique du QuebecCentre de Recherche du CHU de Quebec-Universite LavalSocial and preventive medicine department, Faculty of medicine, Laval University||Biological and occupational risks. Institut national de sante publique du QuebecCentre de Recherche du CHU de Quebec-Universite Laval||Social and preventive medicine department, Faculty of medicine, Laval University||Biological and occupational risks. Institut national de sante publique du QuebecCentre de Recherche du CHU de Quebec-Universite Laval||Social and preventive medicine department, Faculty of medicine, Laval University||Biological and occupational risks. Institut national de sante publique du QuebecBiological and occupational risks. Institut national de sante publique du QuebecCentre de Recherche du CHU de Quebec-Universite Laval||Social and preventive medicine department, Faculty of medicine, Laval UniversityCommunicable Diseases and Immunization Services, BC Centre for Disease Control
预防医学医学研究方法医药卫生理论
SARS-CoV-2COVID-19vaccine effectivenesshealthcare workerstest-negative design
Deceuninck Genevi¨¨ve,Brousseau Nicholas,Carignan Alex,De Wals Philippe,Barkati Sapha,Drolet M¨|lanie,Brisson Marc,Boulianne Nicole,Ouakki Manale,Carazo Sara,Sauvageau Chantal,Gilca Rodica,De Serres Gaston,Fortin Elise,Talbot Denis,Skowronski Danuta M..Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada[EB/OL].(2025-03-28)[2025-08-02].https://www.medrxiv.org/content/10.1101/2021.07.19.21260445.点此复制
评论